Astrazeneca (AZN) Research & Development (2009 - 2026)

Astrazeneca (AZN) has reported Research & Development for 18 consecutive years, with -$3.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 10.54% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$14.6 billion (down 4.34% YoY), while the FY2025 annual figure was $14.2 billion, up 4.78% from the prior year.
• Research & Development came in at -$3.5 billion for Q1 2026 at Astrazeneca, up from -$3.9 billion in the prior quarter.
• The five-year high for Research & Development was -$2.1 billion in Q1 2022, with the low at -$4.7 billion in Q4 2024.
• Average Research & Development over 5 years is -$3.1 billion, with a median of -$3.0 billion recorded in 2024.
• Across the five-year window, Research & Development surged 31.91% in 2022 and tumbled 52.2% in 2024, its largest moves.
• Year by year, Research & Development stood at -$2.6 billion in 2022, then fell by 17.07% to -$3.1 billion in 2023, then sank by 52.2% to -$4.7 billion in 2024, then rose by 17.43% to -$3.9 billion in 2025, then rose by 9.58% to -$3.5 billion in 2026.
• According to Business Quant data, Research & Development over the past three periods registered -$3.5 billion, -$3.9 billion, and -$3.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.